2. Academic Validation
  3. Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases

Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases

  • J Med Chem. 2013 Mar 14;56(5):1799-810. doi: 10.1021/jm301465a.
Juan-Miguel Jimenez 1,  Dean Boyall,  Guy Brenchley,  Philip N Collier,  Christopher J Davis,  Damien Fraysse,  Shazia B Keily,  Jaclyn Henderson,  Andrew Miller,  Francoise Pierard,  Luca Settimo,  Heather C Twin,  Claire M Bolton,  Adam P Curnock,  Peter Chiu,  Adam J Tanner,  Stephen Young
Affiliations

Affiliation

  • 1 Department of Chemistry, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, UK. juan-miguel_jimenez@vrtx.com
PMID: 23398373 DOI: 10.1021/jm301465a
Abstract

Protein kinase C θ (PKCθ) has a central role in T cell activation and survival; however, the dependency of T cell responses to the inhibition of this Enzyme appears to be dictated by the nature of the antigen and by the inflammatory environment. Studies in PKCθ-deficient mice have demonstrated that while Antiviral responses are PKCθ-independent, T cell responses associated with autoimmune diseases are PKCθ-dependent. Thus, potent and selective inhibition of PKCθ is expected to block autoimmune T cell responses without compromising Antiviral immunity. Herein, we describe the development of potent and selective PKCθ inhibitors, which show exceptional potency in cells and in vivo. By use of a structure based rational design approach, a 1000-fold improvement in potency and 76-fold improvement in selectivity over closely related PKC isoforms such as PKCδ were obtained from the initial HTS hit, together with a big improvement in lipophilic efficiency (LiPE).

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z